Some patients may experience mild injection site reactions, but these are typically temporary
Wegovy is now uniquely positioned as the first and only GLP-1 treatment approved for MASH, complementing the already proven weight loss, cardiovascular benefits and extensive body of evidence linked to semaglutide, said Martin Holst Lange, executive vice president, chief scientific officer and head of Research and Development, at Novo Nordisk
Additionally, semaglutide injections offer heart health benefits, as they help lower the risk of major cardiovascular events like heart attacks or strokes
Antioxidant and anti-fatigue activities of egg white peptides prepared by pepsin digestion
Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction